Fundraising FoxBain Capital Life Sciences — 2020 Investments
6 investments dated 2020 · listed companies and verified rows first · show all
Solid Biosciences is a precision genetic medicine company developing a pipeline of gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, CPVT, and TNNT2-mediated dilated cardiomyopathy.
BiotechHealthtechCharlestown, US
Ilan Ganot(Co-Founder and Director)inStephen DiPalma(Executive Officer)Carl Morris(Executive Officer)inAlexander Cumbo(President, Chief Executive Officer and Director)Martin Freed(Director)inPaul Herizch(Executive Officer)
Board seatAdam M. Koppel· per SEC Form D
Co-investorsForesite CapitalRA CapitalBain Capital
JenaValve develops transcatheter aortic valve replacement systems to treat severe aortic regurgitation and aortic stenosis.
Digital HealthHealthtechMedical DevicesIrvine, US
Hans Figulla(Director)Markus FerrariVictoria Carr-Brendel(Executive Officer, Director)David Drachman(Executive Officer, Director)John Kilcoynein
.jpg)
BoardArnd Kaltofen(Director)in
Board seatAndrew Hack· per SEC Form D
Co-investorsAndera PartnersRosetta Capital Ltd.VI PartnersAtlas VentureGimvInnovatus Capital Partners+5 more
Annexon is a clinical-stage biopharmaceutical company developing C1q and classical complement pathway inhibitors to treat complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders.
BiotechHealthtechMedical DevicesSo. San Francisco, US
Ben Barres(Scientific Co-Founder)Douglas Love(Founder)inMark L Smith(Executive Officer)Campbell Murray(Director)inThomas Wiggans(Director)Ricky Sun(Director)
Co-investorsCorrelation VenturesNew Enterprise Associates (NEA)BlackRockBlackstone Life SciencesClarus VenturesDeerfield Management Company+2 more
CereVasc is developing the eShunt System, a minimally invasive device intended to treat communicating hydrocephalus in children and adults as an alternative to invasive neurosurgical procedures.
BiotechHealthtechMedical DevicesAuburndale, US
Carl Heilman(Director)Daniel Levangie(Executive Officer, Director)inLeslie Teso-Lichtman(Executive Officer)inFrederick Callori(Director)Patrick Sullivan(Director)Aaron Levangie(Executive Officer)
Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.
BiotechCambridge, US
Nancy Simonian(CEO)Peter Wirth(Director)Mark Alles(Director)Philip Sharp(Director)Richard A. Young(Director)Sue Gail Eckhardt(Director)
Co-investorsAisling CapitalARCH Venture PartnersQuan CapitalAlexandriaAlly Bridge GroupBain Capital+11 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.